ICON Public Limited Company Total Liabilities
ICON Public Limited Company total liabilities. Based on the latest financial reports, ICON Public Limited Company (IJF) has total liabilities worth €7.17 Billion EUR (≈ $8.39 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IJF asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ICON Public Limited Company (2016–2024)
Total liabilities of ICON Public Limited Company from 2016 to 2024. This chart illustrates how ICON Public Limited Company's total liabilities have evolved over time, based on quarterly financial data. Explore ICON Public Limited Company long-term investment intensity to see how much of total assets are deployed in long-term investments.
ICON Public Limited Company Competitors by Total Liabilities
The table below lists competitors of ICON Public Limited Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NEW ORIENTAL EDU.+TECH.G.
F:N1U0
|
Germany | €3.83 Billion |
|
Yuanjie Semiconductor Technology Co. Ltd. A
SHG:688498
|
China | CN¥118.84 Million |
|
NTPC Green Energy Limited
NSE:NTPCGREEN
|
India | Rs295.73 Billion |
|
INPOST S.A UNSP.ADR/1/2
F:6690
|
Germany | €14.24 Billion |
|
NISSAN MOTOR SP. ADR/2
F:NISE
|
Germany | €13.97 Trillion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $95.94 Million |
|
Pearson plc
F:PESA
|
Germany | €2.79 Billion |
|
Huadian Power International Corp Ltd Class A
SHG:600027
|
China | CN¥158.53 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down ICON Public Limited Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ICON Public Limited Company total assets.
Liquidity & Leverage Metrics
ICON Public Limited Company Total Liabilities Ratios Explained
ICON Public Limited Company total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ICON Public Limited Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ICON Public Limited Company (2016–2024)
The table below shows the annual total liabilities of ICON Public Limited Company from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €7.35 Billion ≈ $8.60 Billion |
-5.09% |
| 2023-12-31 | €7.75 Billion ≈ $9.06 Billion |
-10.79% |
| 2022-12-31 | €8.69 Billion ≈ $10.16 Billion |
-6.80% |
| 2021-12-31 | €9.32 Billion ≈ $10.90 Billion |
+487.89% |
| 2020-12-31 | €1.59 Billion ≈ $1.85 Billion |
+22.95% |
| 2019-12-31 | €1.29 Billion ≈ $1.51 Billion |
+28.95% |
| 2018-12-31 | €999.97 Million ≈ $1.17 Billion |
+4.64% |
| 2017-12-31 | €955.62 Million ≈ $1.12 Billion |
+8.51% |
| 2016-12-31 | €880.67 Million ≈ $1.03 Billion |
-- |
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more